Loading…
COVONIA NIGHT TIME FORMULA is a brand name for Diphenhydramine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the night time symptomatic relief of unproductive cough and congestive symptoms associated with colds.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults, the Elderly and Children over 12 years 3 x 5ml spoonfuls at bedtime. Repeat after 6 hours if required. Children under 12 years Do not give to children under 12 years old.
The following undesirable effects have been reported for use of dextromethorphan or sedating antihistamines including diphenhydramine, and may arise from use of Covonia Night Time Formula. The frequency of adverse effects cannot be estimated from available data.
Undesirable effects may be attributable to both dextromethorphan and sedating antihistamines unless otherwise stated. 4) Nervous system disorders: Drowsiness and lowered ability to concentrate, dizziness, convulsions Extrapyramidal effects, paradoxical stimulation, headache, psychomotor impairment, tremor, paraesthesias, sleep disturbances (attributable to sedating antihistamines) Eye disorders: Blurred vision, angle-closure glaucoma (attributable to sedating antihistamines) Ear and labyrinth disorders: Tinnitus (attributable to sedating antihistamines) Cardiac disorders: Palpitations, arrhythmias (attributable to sedating antihistamines) Vascular disorders: Hypotension (attributable to sedating antihistamines) Respiratory, thoracic and mediastinal disorders: Respiratory depression (attributable to dextromethorphan) Thickened respiratory tract secretions, Bronchospasm (attributable to sedating antihistamines) Gastrointestinal disorders: Gastrointestinal disturbances (including nausea, vomiting, diarrhoea) Dry mouth (attributable to sedating antihistamines) Hepatobiliary disorders: Liver dysfunction (attributable to sedating antihistamines) Skin and subcutaneous tissue disorders: Hypersensitivity reactions including skin rash Angioedema, sweating, hair loss (attributable to sedating antihistamines) Musculoskeletal, connective tissue and bone disorders: Myalgia (attributable to sedating antihistamines) Renal and urinary disorders: Urinary retention (attributable to sedating antihistamines) General disorders and administration site conditions: Anaphylaxis (attributable to sedating antihistamines) Drug withdrawal syndrome Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Because of their antimuscarinic properties antihistamines should be used with care in conditions such as closed angle glaucoma, urinary retention, prostatic hyperplasia or pyeloduodenal obstruction. Caution should also be exercised in patients with epilepsy or severe cardiovascular disorders.
Caution is needed for the use of dextromethorphan in patients with a history of asthma, or with chronic or persistent cough. This medicine should be used with caution in atopic children due to histamine release. 5). Dextromethorphan is metabolised by hepatic cytochrome P450 2D6.
The activity of this enzyme is genetically determined. About 10% of the general population are poor metabolisers of CYP2D6. Poor metabolisers and patients with concomitant use of CYP2D6 inhibitors may experience exaggerated and/or prolonged effects of dextromethorphan.
5).
Labels will state:
If symptoms persist consult your doctor. Keep out of the sight and reach of children. Do not take more medicine than the label tells you to.
Do not take with any other cough and cold medicine Warning:
This medicine may make you feel sleepy. If this happens do not drive or use tools or machines. Do not drink alcohol. Can cause addiction. This medicine may cause opioid-like effects when used at high doses. Drug dependence, tolerance and potential for abuse For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses.
, major depression). Drug withdrawal syndrome The drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations.
Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
Contraindicated in known hypersensitivity to any of the ingredients. Contraindicated in persons under treatment with monoamine oxidase inhibitors or within 2 weeks of discontinuation of MAOI use. Contraindicated in persons under treatment with selective serotonin reuptake inhibitors (SSRIs) Dextromethorphan, in common with other centrally acting antitussive agents, should not be given to patients in, or at risk of developing, respiratory failure.
Covonia Night Time Formula should not be used in liver dysfunction. It should not be administered to patients where cough is associated with asthma, or patients with productive cough. Diphenhydramine has been associated with acute attacks of porphyria and is considered unsafe in porphyric patients.
Do not give to children under 12 years old.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Diphenhydramine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for ‘MHRA Yellow Card’ in the Google Play or Apple App Store.
Serotonin Syndrome Serotonergic effects, including the development of a potentially life- threatening serotonin syndrome, have been reported for dextromethorphan with concomitant administration of serotonergic agents, such as selective serotonin re-uptake inhibitors (SSRIs), drugs which impair metabolism of serotonin (including monoamine oxidase inhibitors (MAOIs)) and CYP2D6 inhibitors.
Serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with Covonia Night Time Formula should be discontinued.
Ingredients with specified warnings This medicine contains less than 1mmol sodium (23mg) per 15ml dose, that is to say essentially ‘sodium-free’. This medicine contains 18mg Sodium benzoate in each 15ml dose. 675g Sorbitol in each 15ml dose.
Patients with rare hereditary fructose intolerance (HFI) should not take/be given this medicinal product. This medicine contains 880mg of alcohol (ethanol) in each 15ml dose. The amount in 15ml of this medicine is equivalent to less than 22ml of beer or 9ml of wine.
The small amount of alcohol in this medicine is unlikely to have any noticeable effects.